血药浓度监测在甲氨蝶呤治疗急性淋巴细胞性白血病中的意义

The significance of therapeutic drug monitoring on methotrexate in the treatment of acute lymphoblastic leukemia

目的探讨血药浓度监测在甲氨蝶呤治疗急性淋巴细胞性白血病患者中的意义。方法采用均相酶扩大免疫法(EMIT)对使用甲氨蝶呤后24 h、48 h、72 h的血药浓度进行监测。结果对20例患者进行43次的甲氨蝶呤浓度测定,其中仅有1例患者出现了甲氨蝶呤排泄延迟的情况。结论在临床治疗急性淋巴细胞性白血病中,进行甲氨蝶呤血药浓度监测是必要的,同时要时刻观察患者用药时出现的不良反应,并及时进行相应的处理。

Objective To investigate the significance of therapeutic drug monitoring of methotrexate in the treatment of acute lymphoblastic leukemia patients. Methods EMIT was used to determine the concentrations of methotrexate in 24 h/48 h/72 h. Results 20 patients were measured the concentrations of methotrexate at 43 times, and delayed MTX elimination was seen in one of them. Conclusion It is necessary to monitor the concentration of methotrexate, and at the same time to observe the adverse reaction of the patients, which is good to deal with adverse drug reaction in time.